Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Evidence-based use of levosimendan in different clinical settings De Luca L; Colucci WS; Nieminen MS; Massie BM; Gheorghiade MEur Heart J 2006[Aug]; 27 (16): 1908-20Levosimendan is a new calcium sensitizer and K-ATP channel opener. Compared with other inodilators, it improves myocardial contractility without increasing oxygen requirements and induces peripheral and coronary vasodilation with a potential anti-stunning, anti-ischaemic effect. The documentation regarding levosimendan is one of the largest ever on the safety and efficacy of a new pharmacological agent in acute heart failure syndromes. Recent experiences in small-scale studies and randomized clinical trials have led to greater interest in the use of this drug for the support of impaired cardiac function also in patients with ischaemic heart disease and cardiogenic or septic shock. It is also demonstrated that this drug could be used as bridge therapy for the peri-operative phase of cardiac surgery in both adult and paediatric populations. This review summarizes the evidence from published scientific literature regarding the use of levosimendan in various clinical settings.|Administration, Oral[MESH]|Adult[MESH]|Arrhythmias, Cardiac/chemically induced[MESH]|Cardiotonic Agents/pharmacology/*therapeutic use[MESH]|Child[MESH]|Heart Failure/*drug therapy[MESH]|Humans[MESH]|Hydrazones/pharmacology/*therapeutic use[MESH]|Intraoperative Care[MESH]|Myocardial Ischemia/*drug therapy[MESH]|Pyridazines/pharmacology/*therapeutic use[MESH]|Randomized Controlled Trials as Topic[MESH]|Shock, Cardiogenic/*drug therapy[MESH]|Simendan[MESH] |
